← Back to news
April 18, 2026
Trump signs executive order to expedite review of psychedelics for mental health disorders
- President Donald Trump signed an executive order to fast-track the FDA's review of psychedelics, including ibogaine and psilocybin, to treat mental health conditions like PTSD, depression, and anxiety.
- The order allocates $50 million in federal funds to improve access to these substances, marking a significant shift in their regulatory status.
- Next week, the FDA will issue national priority vouchers for three psychedelics, enabling rapid approval processes for their use.
5 Sources
- Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugsApr 18, 2026 at 1:25 PM · Fox News
- Joe Rogan joins Trump to sign order allowing psychedelic drug researchApr 18, 2026 at 2:19 PM · The Hill
- Trump signs order to speed review of psychedelics, including the controversial drug ibogaineApr 18, 2026 at 2:25 PM · CNBC
- President Trump signed an executive order Saturday that seeks to fast-track research into certain psychedelic drugs used to treat PTSD and other disordersApr 18, 2026 at 5:19 PM · WSJ
- Trump signs order fast tracking review of psychedelics for mental health disordersApr 18, 2026 at 6:56 PM · NPR